PDF(Pubmed)
Abstract：
Multiple myeloma is a malignant cancerous condition that is characterized by abnormal plasma cell production and can lead to bone destruction due to increased osteoclastic activity and decreased osteoblastic activity. Many therapeutic therapies are used to treat diseases, such as chemotherapy and radiotherapy. In recent years, anti-sclerostin antibody treatment has been under investigation for its effect on the multiple myeloma. The present study was conducted to assess the effective therapeutic use of anti-sclerostin antibody in the treatment of multiple myeloma. The literature search was conducted using PubMed, Google Scholar, ScienceDirect, and PubMed Central using the following MeSH terms: \"multiple myeloma\", \"anti-sclerostin antibody\", \"ubiquitin-proteasome pathway\", \"proteasome inhibitor\", \"Wnt pathway\". A total of 348 articles were screened. Twenty-five out of 348 were full-text articles assessed for eligibility, and four articles were used in this systematic review. The Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines were used for the reporting of this systematic review. A total of four randomized control trials (RCT) were included and used in this systematic review. The anti-sclerostin antibodies were various other drugs, and it was found that the anti-sclerostin antibody was effective in preventing autoantibody formation, decreasing bone destruction, and increasing trabecular bone. Anti-sclerostin antibody was found to be effective in decreasing bone destruction by reducing osteoclastic activity and increasing osteoblastic activity associated with multiple myeloma.
摘要：
多发性骨髓瘤是一种恶性癌性疾病，其特征在于浆细胞产生异常，并且由于破骨细胞活性增加和成骨细胞活性降低而导致骨破坏。许多治疗疗法用于治疗疾病，如化疗和放疗。近年来,抗硬化蛋白抗体治疗对多发性骨髓瘤的影响一直在研究中。本研究旨在评估抗硬化蛋白抗体在多发性骨髓瘤治疗中的有效治疗用途。文献检索使用PubMed，谷歌学者，ScienceDirect,和PubMedCentral使用以下MeSH术语：“多发性骨髓瘤”，“抗硬化蛋白抗体”，“泛素-蛋白酶体途径”，“蛋白酶体抑制剂”，“Wnt通路”。共筛选了348篇文章。348篇文章中有25篇是评估合格性的全文文章,本系统综述使用了四篇文章。系统评价和荟萃分析（PRISMA）指南的首选报告项目用于本系统评价的报告。本系统综述共纳入并使用了4项随机对照试验(RCT)。抗硬化蛋白抗体是各种其他药物，发现抗硬化蛋白抗体能有效防止自身抗体的形成，减少骨骼破坏，增加骨小梁.发现抗硬化蛋白抗体通过减少破骨细胞活性和增加与多发性骨髓瘤相关的成骨细胞活性而有效减少骨破坏。
